The media database brings together all published information on platforms and products, as well as financial and corporate news.
Join our mailing list.
12/12/2024
ADOCIA and Tonghua Dongbao Announce the Final Dosing in a Phase 3 Clinical Study of BioChaperone® Lispro, Milestone Associated with a $10 Million Payment

10/15/2024
ADOCIA announces patenting stable combinations of GLP-1 and amylin analogs for the treatment of obesity and diabetes using its BioChaperone® platform

07/10/2024
ADOCIA Announces that Tonghua Dongbao is Discontinuing one of the two Partnership Programs: BioChaperone® Combo

06/18/2024
ADOCIA Announces Three Presentations at the American Diabetes Association 84th Scientific Sessions

04/24/2024
ADOCIA Announces Full Year 2023 Financial Results and Provides a Corporate and Financial Update

03/21/2024
ADOCIA Announces a €2 Million Fundraising from its two Main Shareholders and a Member of its Management, and the Signature of an Equity Financing Line with Vester Finance

11/09/2023
ADOCIA Revealed Promising Preclinical Data on AdoShell® Islets for Cell Therapy of Diabetes

10/25/2023
ADOCIA Reports Financial Results of Third Quarter 2023 and Provides an Update on its Activities

10/23/2023
ADOCIA’s Partner Tonghua Dongbao Announces Positive Results of Three Clinical Trials on BioChaperone® Combo

09/25/2023
ADOCIA Announces Oral Presentations on AdoShell® Islets at EASD and IPITA-IXA-CTRMS Congresses

08/31/2023
ADOCIA Announces that it has Received €500.000 in Proceeds from a Partial Exercise of Warrants Held by IPF Partners

07/05/2023
ADOCIA Grants Sanofi an Exclusive Right to Negotiate a Partnership on M1Pram for 10 Million Euros and Obtains Commitment from Investors to Provide 10 Million Euros in Financing

04/25/2023
ADOCIA Reports Financial Results of First Quarter 2023 and Provides an Update on its Activities

12/01/2022
Adocia strengthens its cash position with EUR 6 million through the issuance of convertible bonds subscribed by European investors in order to accelerate the development of key products

10/25/2022
ADOCIA Reports its Cash Position and Revenue for the Third Quarter of 2022 and Provides Business Updates

10/06/2022
ADOCIA Announces Exceptional Weight Loss for Obese People with Type 1 Diabetes using M1Pram in a post-hoc analysis

09/15/2022
ADOCIA Will Release its 2022 Half-Year Results on September 19th and Hold a Webinar on September 20th

09/07/2022
ADOCIA Announces First Cell Therapy Preclinical Proof of Concept of AdoShell® Islets for the Treatment of Type 1 Diabetes

06/21/2022
ADOCIA announces M1Pram Phase 2 Trial Meets Primary Objective by Reducing Weight in Overweight People with Type 1 Diabetes

05/18/2022
ADOCIA Announces The First Subject Treated In BioChaperone® Combo Clinical Studies with Partner Tonghua Dongbao

05/09/2022
ADOCIA Announces the First Patient Dosed In the BioChaperone® Lispro Phase 3 Program with Partner Tonghua Dongbao

04/11/2022
ADOCIA Announces Start of 3 Clinical Studies for BioChaperone® Combo with Partner Tonghua Dongbao

03/28/2022
Adocia strengthens its cash position by 19 million euros following a real estate transaction

Join our mailing list. Subscribe